Wegovy for Weight Management: How the Injectable Medication Fits Into Daily Life

Wegovy is an injectable prescription medicine used in adults with obesity or overweight plus at least one weight-related condition as part of a long-term weight management plan that also includes a reduced-calorie diet and increased physical activity FDA, 01/2024.

As of: 06/06/2026 | Reading time: approx. 6 minutes

By the AD HOC NEWS editorial team - specialized in product-focused market coverage.

What Wegovy Is and How It Works

Wegovy is a once-weekly injectable medicine containing the active ingredient semaglutide, a glucagon-like peptide-1 receptor agonist used for chronic weight management in adults who meet specific body weight and health criteria Novo Nordisk, 03/2024.

The medication is supplied as a prefilled, single-patient-use injection pen designed for subcutaneous use, typically in the abdomen, thigh, or upper arm, with dosing initiated at a lower level and gradually increased according to the prescribing information FDA, 01/2024.

Wegovy acts as a GLP-1 receptor agonist, which means it mimics the activity of the human incretin hormone GLP-1 to help regulate appetite and food intake as part of a comprehensive weight management program when used with diet and physical activity Novo Nordisk, 03/2024.

Why Wegovy Matters for US Consumers and Industry

For US adults with obesity or overweight plus certain health conditions, Wegovy represents an additional prescription option for long-term weight management alongside lifestyle changes under medical supervision FDA, 06/2021.

The product is part of a broader clinical and public health focus on chronic weight management in the United States, where obesity is recognized by federal health authorities as a complex, long-term condition that can require sustained treatment strategies including medications approved for this purpose CDC, 09/2023.

Wegovy is used under a prescription from licensed US health care providers, and its use is accompanied by guidance on diet, physical activity, and ongoing monitoring, reflecting the emphasis in US clinical practice on combined approaches to chronic weight management NIDDK, 02/2024.

Wegovy in the US and Global Market

In the US market, Wegovy is one of several prescription medications indicated for chronic weight management, prescribed to adults who meet criteria in the product labeling and who are engaged in a structured plan that includes nutrition and physical activity under medical care NIDDK, 02/2024.

The medication is marketed by Novo Nordisk as part of its portfolio in obesity care and is available in the United States subject to federal and state regulations for prescription drugs, as well as coverage decisions by health plans and pharmacy benefit managers Novo Nordisk, 01/2024.

Wegovy is also part of an international obesity care portfolio offered in selected countries where it has received regulatory authorization, but prescribing and reimbursement conditions differ by market based on local health system frameworks and regulatory decisions Novo Nordisk, 01/2024.

• Prescription-only injection used with diet and activity
• Once-weekly dosing schedule for chronic use
• Intended for adults meeting specific criteria
• Part of a broader obesity care portfolio

Frequently Asked Questions About Wegovy

Who is Wegovy generally prescribed for?
Wegovy is generally prescribed for adults with obesity or overweight plus at least one weight-related condition, as described in the FDA-approved prescribing information.

How often is Wegovy typically taken?
Wegovy is taken once a week as a subcutaneous injection, following the dosing schedule and titration plan in the prescribing information.

Is Wegovy available in the United States?
Yes, Wegovy is available as a prescription medication in the United States, subject to regulatory requirements and coverage decisions.

Novo Nordisk is the pharmaceutical company that develops and markets Wegovy as part of its global obesity care and diabetes care portfolio.

The issuer of the shares associated with ISIN DK0060534915 is Novo Nordisk, which is listed on regulated markets in Europe and the United States through its share and depositary receipt programs.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.